US and EU regulators begin offering parallel scientific advice to generic drugmakers
The FDA and European Medicines Agency collaborate often and meet regularly, but the two drug regulators have now announced that for the first time, they will begin offering parallel scientific advice for generic drugmakers as part of a pilot project.
The parallel advice will begin for complex generic drugs as part of a voluntary pilot project that expands upon FDA and EMA’s parallel advice for new drugs and biologics.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.